B. Braun Avitum Poland Dialysis Center, Sienkiewicza str. 3, Nowy Tomyśl 64-300, Poland.
Int Urol Nephrol. 2010 Jun;42(2):441-52. doi: 10.1007/s11255-009-9525-1. Epub 2009 Jan 31.
BACKGROUND/AIMS: To examine plasma levels of visfatin and endogenous secretory receptor for advanced glycation end-products (esRAGE) in diabetic and non-diabetic patients treated with intermittent hemodialysis (IHD), and to explore the possible associations between them, insulin resistance evaluated by homeostasis model assessment for insulin resistance (HOMA-IR), as well as selected biochemical and anthropometric parameters.
The study was carried out in 65 IHD patients. Type 2 diabetic patients (n = 28) were included into group I, non-diabetics (n = 37)-into group II. The reference group included 25 healthy volunteers.
There were no significant differences between group I and II in plasma level of visfatin and esRAGE. HOMA-IR was higher in group I than in group II. In both groups these parameters were higher than in healthy subjects. In group I, visfatin correlated with insulin concentration (r = 0.428, P = 0.023), HOMA-IR with esRAGE (r = -0.374, P = 0.049). In group II, esRAGE correlated with waist-to-hip ratio (r = -0.343, P = 0.037), HOMA-IR with body mass index (r = 0.499, P = 0.001) and LDL cholesterol (r = -0.384, P = 0.018).
Serum concentrations of visfatin and esRAGE are increased in IHD patients. There is no difference in visfatin and esRAGE levels between diabetic and non-diabetic IHD patients. In diabetic IHD patients receiving insulin, lower esRAGE levels are associated with higher insulin resistance, whereas plasma visfatin level is positively related to plasma insulin concentration. Waist-to-height ratio is a significant determinant of plasma visfatin level and HOMA-IR. Insulin resistance seems to be a link between esRAGE and visfatin in IHD diabetics.
背景/目的：检测接受间歇性血液透析（IHD）治疗的糖尿病和非糖尿病患者的血浆内脏脂肪素和晚期糖基化终产物内源性受体（esRAGE）水平，并探讨它们与胰岛素抵抗评估的稳态模型评估的胰岛素抵抗（HOMA-IR）以及其他生化和人体测量参数之间的可能关联。
该研究共纳入 65 名 IHD 患者。28 例 2 型糖尿病患者纳入 I 组，37 例非糖尿病患者纳入 II 组。参考组包括 25 名健康志愿者。
I 组和 II 组血浆内脏脂肪素和 esRAGE 水平无显著差异。I 组的 HOMA-IR 高于 II 组。两组的这些参数均高于健康对照组。在 I 组中，内脏脂肪素与胰岛素浓度呈正相关（r = 0.428，P = 0.023），HOMA-IR 与 esRAGE 呈负相关（r = -0.374，P = 0.049）。在 II 组中，esRAGE 与腰臀比呈负相关（r = -0.343，P = 0.037），HOMA-IR 与体重指数（r = 0.499，P = 0.001）和 LDL 胆固醇（r = -0.384，P = 0.018）呈正相关。
IHD 患者血清内脏脂肪素和 esRAGE 浓度升高。糖尿病和非糖尿病 IHD 患者的内脏脂肪素和 esRAGE 水平无差异。在接受胰岛素治疗的糖尿病 IHD 患者中，较低的 esRAGE 水平与较高的胰岛素抵抗相关，而血浆内脏脂肪素水平与血浆胰岛素浓度呈正相关。腰高比是血浆内脏脂肪素水平和 HOMA-IR 的重要决定因素。胰岛素抵抗似乎是 IHD 糖尿病患者 esRAGE 和内脏脂肪素之间的联系。
